Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
US Market
Holding CTNM?
Track your performance easily

Contineum Therapeutics, Inc. Class A (CTNM) Income Statement

159 Followers

Contineum Therapeutics, Inc. Class A Income Statement

Last quarter (Q2 2024), Contineum Therapeutics, Inc. Class A's total revenue was $―, a decrease of -100.00% from previous quarter. In Q2, Contineum Therapeutics, Inc. Class A's net income was $-9.01M. See Contineum Therapeutics, Inc. Class A’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22
Total Revenue
$ 50.00M$ 50.00M-
Cost of Revenue
---
Gross Profit
$ 50.00M$ 50.00M-
Operating Expense
$ 27.69M$ 34.10M$ 22.81M
Operating Income
$ 22.31M$ 15.90M$ -22.81M
Net Non Operating Interest Income Expense
$ 6.27M$ 4.40M$ 373.00K
Other Income Expense
$ -2.33M$ -2.87M$ -1.82M
Pretax Income
$ 30.90M$ 23.17M$ -20.62M
Tax Provision
$ 450.00K$ 450.00K-
Earnings From Equity Interest Net Of Tax
---
Net Income Common Stockholders
$ 30.45M$ 22.72M$ -20.62M
Basic EPS
$ -1.73$ 1.36$ -10.81
Diluted EPS
$ -1.28$ 0.08$ -10.81
Basic Average Shares
$ -6.00M$ 2.31M$ 2.24M
Diluted Average Shares
$ -20.93M$ 3.40M$ 2.24M
Dividend Per Share
---
Total Operating Income As Reported
---
Reported Normalized Basic E P S
---
Reported Normalized Diluted E P S
---
Rent Expense Supplemental
---
Total Expenses
$ 27.69M$ 34.10M$ 22.81M
Net Income From Continuing And Discontinued Operation
$ 30.45M$ 22.72M$ -20.62M
Normalized Income
$ -8.92M--
Interest Expense
---
EBIT
$ -9.01M--
EBITDA
$ -8.71M--
Currency in USD

Contineum Therapeutics, Inc. Class A Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis